The market size of the Global Intracranial Aneurysm Market in the year 2019 is valued at 1.08 billion and is predicted to reach 2.26 billion by the year 2030 at an 8.8% CAGR during the forecast period.
Curious about this latest version of report? Obtain Report [email protected] https://www.insightaceanalytic.com/report/global-intracranial-aneurysm-market/1283
An abnormal focal expansion of an artery caused by a weakening of the blood vessel wall’s inner muscle layer (the intima) is known as a cerebral or intracranial aneurysm. The rise in the number of risk factors for intracranial aneurysms, such as family history, autosomal dominant PCKD, coarctation of the aorta, bicuspid aortic valve, Ehlers-Danlos syndrome type IV, smoking, hypertension, is driving market expansion. Furthermore, the rising number of strokes around the world would have a higher chance of rupturing blood vessels and resulting in an intracranial aneurysm, boosting market revenue growth. The market growth is likely to be driven by an increase in the incidence of brain aneurysms as well as increased use of minimally invasive intracranial aneurysm operations. An intracranial aneurysm is a swelling in the inner wall of a cerebral artery. However, the COVID-19 outbreak in 2020 has had a negative impact on the intracranial aneurysm market by directly hurting demand and production, disrupting the supply chain, and increasing the financial burden on businesses. During this time, brain surgeries have been regularly postponed or even cancelled to prevent the spread of the coronavirus. Also, innovations in medications and treatment methods provide profitable opportunities for market players.
On the other hand, the high expense of treating a brain aneurysm is projected to hinder market expansion. In the forecast future, the lack of effective and customized therapy is expected to be a challenge to the cerebral aneurysm treatment market.
List of Prominent Players in the Intracranial Aneurysm Market:
Micropart Scientific Corporation
Johnson and Johnson Services Inc.
Micronation Inc. (Terumo Corporation)
Codman Neuro (Integra Lifesciences)
For More Information @ https://www.insightaceanalytic.com/report/global-intracranial-aneurysm-market/1283
The market is rising due to an increase in the number of patients suffering from high blood pressure and blood vessel trauma, as well as the growing adoption of hazardous lifestyle behaviours such as smoking, which causes cerebral aneurysm. The market is further positively impacted by the rising acceptance of medical therapies for the treatment of unruptured intracranial aneurysms and the growth in the number of advances in neurodegenerative disease drug discovery. The cerebral aneurysm treatment market is also favourably impacted by the rise in the percentage of smokers who acquire brain cancer, research and development, improved healthcare infrastructure, and a rise in healthcare spending.
The high cost of treating a brain aneurysm, is expected to limit market growth. The lack of effective and customized therapy is projected to be a problem for the cerebral aneurysm treatment industry soon. However, The COVID-19 outbreak in 2020, has had a detrimental influence on the intracranial aneurysm market by directly affecting demand and production, interrupting the supply chain, and putting further financial pressure on enterprises.
The North America Intracranial Aneurysm market is expected to register a major market share in terms of revenue during the forecast period. There is an increasing need for minimally invasive treatments due to the rising incidence of intracranial aneurysms, the expanding desire for minimally invasive procedures, and the rising frequency of hypertension and stroke. In addition, an increase in the occurrence of cerebral aneurysms and a rise in the desire for minimally invasive procedures are both contributing to the region’s market growth. Furthermore, the market expansion is likely to be fueled by a rising number of initiatives being conducted by various organizations. Furthermore, rising healthcare spending and the presence of well-established healthcare infrastructure are both contributing to the overall regional market’s growth.
- In June 2022, Medtronic Private Limited introduced the Pipeline Vantage with Shield Technology, a CE-marked fourth-generation flow diverter for endovascular treatment of brain aneurysms. The Pipeline Vantage with Shield Technology is a revolutionary flow diverter with improved design characteristics for both the delivery system and the implant.
- In November 2020, Stryker Corporation received the USFDA approval for its Nitroform Atlas Stent System for marketing under the HDE. The device has been designed to provide the coil support and wall apposition needed to perform effective stent-assisted coiling procedures.
Segmentation of Intracranial Aneurysm Market-
- Surgical Clipping
- Endovascular Coiling
- Flow Diverters
- Other Types
- Other End-Users”
- The US
- The UK
- Rest of Europe
- South Korea
- South East Asia
- Rest of Asia Pacific
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Request for ToC/Proposal: https://www.insightaceanalytic.com/request-sample/1283